Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
157
-
Total 13F shares, excl. options
-
40.5M
-
Shares change
-
+2.23M
-
Total reported value, excl. options
-
$2.74B
-
Value change
-
+$147M
-
Put/Call ratio
-
0.8
-
Number of buys
-
85
-
Number of sells
-
-79
-
Price
-
$67.78
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2017
194 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2017.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 157 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.5M shares
of 96M outstanding shares and own 42.18% of the company stock.
Largest 10 shareholders include FMR LLC (6.11M shares), Capital Research Global Investors (5.11M shares), WELLINGTON MANAGEMENT GROUP LLP (4.58M shares), BlackRock Inc. (3.17M shares), VANGUARD GROUP INC (2.99M shares), Capital International Investors (2.18M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.67M shares), STATE STREET CORP (1.27M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.24M shares), and CAPITAL GUARDIAN TRUST CO (624K shares).
This table shows the top 157 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.